Stock comparison
ARGENX SE is 6.1x more valuable than ImmunityBio, Inc. by market capitalization ($56.28 B vs $9.29 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
ARGX is larger
ARGENX SE is 6.1x more valuable than ImmunityBio, Inc. by market capitalization ($56.28 B vs $9.29 B).
Market value leader
ARGX
ARGENX SE is 6.1x more valuable than ImmunityBio, Inc. by market capitalization ($56.28 B vs $9.29 B).
| Metric | IBRX | ARGX |
|---|---|---|
| Market cap | $9.29 B | $56.28 B |
| US-listed rank | #1001 | #296 |
| Revenue (latest FY) | $113.29M | - |
| Net income (latest FY) | -$351.50M | - |
| Net margin | -310.3% | - |
| P/E (trailing FY) | - | - |
| SEC filings | 528 | 272 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
ARGENX SE is 6.1x more valuable than ImmunityBio, Inc. by market capitalization ($56.28 B vs $9.29 B).
Full pages: ImmunityBio, Inc. and ARGENX SE, or browse the full rankings.